keyword
MENU ▼
Read by QxMD icon Read
search

prostatic cancer

keyword
https://www.readbyqxmd.com/read/27911486/extended-mortality-results-for-prostate-cancer-screening-in-the-plco-trial-with-median-follow-up-of-15-years
#1
Paul F Pinsky, Philip C Prorok, Kelly Yu, Barnett S Kramer, Amanda Black, John K Gohagan, E David Crawford, Robert L Grubb, Gerald L Andriole
BACKGROUND: Two large-scale prostate cancer screening trials using prostate-specific antigen (PSA) have given conflicting results in terms of the efficacy of such screening. One of those trials, the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, previously reported outcomes with 13 years of follow-up. This study presents updated findings from the PLCO trial. METHODS: The PLCO trial randomized subjects from 1993 to 2001 to an intervention or control arm...
December 1, 2016: Cancer
https://www.readbyqxmd.com/read/27911459/evaluation-of-bone-metastases-by-18f-choline-pet-ct-in-a-patient-with-castration-resistant-prostate-cancer-treated-with-radium-223
#2
Piera Scalzi, Cinzia Baiocco, Sabrina Genovese, Antonella Trevisan, Zuzana Sirotova, Carlo Poti
BACKGROUND: To date, bone metastases remain the main cause of morbidity and mortality in patients with metastatic castration-resistant prostate cancer (mCRPC). Therefore, the combination of accurate early detection of bony disease and effective treatment of these lesions is crucial in the management of mCRPC patients, but clinical trials specifically designed to test novel approaches are currently lacking. CASE DESCRIPTION: This report describes the case of a 74-year-old male with bone mCRPC and symptomatic and biochemical progression, who underwent radium-223 therapy, following previous treatment failure...
December 2, 2016: Urologia
https://www.readbyqxmd.com/read/27911129/socioeconomic-position-and-mortality-among-patients-with-prostate-cancer-influence-of-mediating-factors
#3
Signe Benzon Larsen, Klaus Brasso, Jane Christensen, Christoffer Johansen, Anne Tjønneland, Søren Friis, Peter Iversen, Susanne Oksbjerg Dalton
INTRODUCTION: Men with low socioeconomic position experience higher mortality after a prostate cancer diagnosis compared to men with a higher socioeconomic position, however, the specific mediators of this association are unclear. We therefore evaluated the influence of potential mediators on the association between socioeconomic position, and prostate cancer-specific and all-cause death in prostate cancer patients. MATERIALS AND METHODS: We conducted a cohort study of prostate cancer patients in the Danish Diet, Cancer and Health study...
December 2, 2016: Acta Oncologica
https://www.readbyqxmd.com/read/27910903/prostate-cancer-patients-negative-biopsy-controls-discrimination-by-untargeted-metabolomics-analysis-of-urine-by-lc-qtof-upstream-information-on-other-omics
#4
M A Fernández-Peralbo, E Gómez-Gómez, M Calderón-Santiago, J Carrasco-Valiente, J Ruiz-García, M J Requena-Tapia, M D Luque de Castro, F Priego-Capote
The existing clinical biomarkers for prostate cancer (PCa) diagnosis are far from ideal (e.g., the prostate specific antigen (PSA) serum level suffers from lack of specificity, providing frequent false positives leading to over-diagnosis). A key step in the search for minimum invasive tests to complement or replace PSA should be supported on the changes experienced by the biochemical pathways in PCa patients as compared to negative biopsy control individuals. In this research a comprehensive global analysis by LC-QTOF was applied to urine from 62 patients with a clinically significant PCa and 42 healthy individuals, both groups confirmed by biopsy...
December 2, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27910803/the-prognostic-and-predictive-value-of-tmprss2-erg-gene-fusion-and-erg-protein-expression-in-prostate-cancer-biopsies
#5
Kasper Drimer Berg
BACKGROUND: The clinical course of prostate carcinoma (PCa) is very heterogeneous. Consequently, a personalised approach for risk stratification and treatment planning is important. Recently, it has become evident that PCa, also at the genomic level, is heterogeneous. An early and common alteration is the gene fusion between the transmembrane protease serine 2 (TMPRSS2) gene and the v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) gene resulting in expression of the oncoprotein ERG...
December 2016: Danish Medical Journal
https://www.readbyqxmd.com/read/27910797/staging-practice-for-prostate-cancer-varies-and-is-not-in-line-with-clinical-guidelines
#6
Lars J Petersen, Yuliya Shuytsky, Helle D Zacho
INTRODUCTION: The objective was to describe regional variations in M-staging in patients with newly diagnosed prostate cancer within a Danish county and to compare clinical practice with guideline recommendations. METHODS: Data were as captured from 1) a prospective, non-interventional study counting 635 consecutive patients referred for M-staging in the 2008-2009 period at three regional hospitals within one county, and 2) a questionnaire on M-staging practice completed by the five sites performing M-staging in the same county in 2015...
December 2016: Danish Medical Journal
https://www.readbyqxmd.com/read/27910783/recent-advances-and-challenges-in-studies-of-control-of-cancer-stem-cells-and-the-gut-microbiome-by-the-trametes-derived-polysaccharopeptide-psp-review
#7
Joseph M Wu, Barbara B Doonan, Tze-Chen Hsieh, Qingyao Yang, Xiao-Tong Yang, Ming-Tat Ling
The medicinal mushroom Trametes versicolor has been well recognized for its activity in maintaining the general health of the population and in managing and treating human diseases in various cultures. Its use has been recently gaining acceptance and popularity in Western countries. The reported health benefits of T. versicolor led to a search for the identity of its bioactive ingredients. These efforts have resulted in the isolation of the polysaccharopeptide PSP from cultured mycelia of strain Cov-1, which expresses large amounts of PSP...
2016: International Journal of Medicinal Mushrooms
https://www.readbyqxmd.com/read/27910728/predictive-factors-associated-with-biochemical-recurrence-following-radical-prostatectomy-for-pathological-t2-prostate-cancer-with-negative-surgical-margins
#8
Fouad Aoun, Simone Albisinni, Benjamin Henriet, Bertrand Tombal, Roland Van Velthoven, Thierry Roumeguère
OBJECTIVE: The aim of this study was to determine factors associated with the development of biochemical recurrence (BCR) following radical prostatectomy in patients with pathological T2 prostate cancer and negative surgical margins. MATERIALS AND METHODS: This retrospective multicentre cohort study included 1252 consecutive patients with pT2 pN0/Nx and negative surgical margins on radical prostatectomy and without any adjuvant treatment, performed in three Belgian centres...
December 2, 2016: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/27910200/percutaneous-sacroplasty-for-painful-bone-metastases-a-case-report
#9
Jaclyn Yoong, Ronil Vikesh Chandra, Leeroy William, Michael Franco, Tony Goldschlager, Fiona Runacres, Peter Poon
The occurrence of bone metastases is common in patients with advanced cancer. Metastatic bone disease occurs across a range of tumor types, with prostate and breast cancers having the highest incidence. Bone metastases, and associated skeletal-related events, are the most common cause of cancer-related pain. This article is protected by copyright. All rights reserved.
December 2, 2016: Pain Practice: the Official Journal of World Institute of Pain
https://www.readbyqxmd.com/read/27909909/obesity-biomarkers-metabolism-and-risk-of-cancer-an-epidemiological-perspective
#10
Katharina Nimptsch, Tobias Pischon
Obesity is associated with metabolic alterations that may pose a biological link between body fatness and risk of cancer. Elucidating the role of obesity-related biomarkers in cancer development is essential for developing targeted strategies aiming at obesity-associated cancer prevention. Molecular epidemiological studies of the past decades have provided evidence that major hormonal pathways linking obesity and cancer risk include the insulin and insulin-like growth factor-1 (IGF-1) axis, sex-steroid hormones, adipokines and chronic low-grade inflammation...
2016: Recent Results in Cancer Research
https://www.readbyqxmd.com/read/27909906/obesity-and-prostate-cancer
#11
Yin Cao, Edward Giovannucci
Prostate cancer is a complex, heterogeneous disease. Factors related to detection, particularly PSA screening, further increase heterogeneity in the manifestation of the disease. It is thus not possible to provide a simple summary of the relationship between obesity and prostate cancer. Findings on obesity, often defined using body mass index (BMI), and total prostate cancer risk have been mixed; however, obesity is relatively consistently associated with a higher risk of aggressive prostate cancer, with aggressiveness defined in various ways (e...
2016: Recent Results in Cancer Research
https://www.readbyqxmd.com/read/27909899/obesity-and-risk-of-cancer-an-introductory-overview
#12
Tobias Pischon, Katharina Nimptsch
The prevalence of obesity has increased substantially in the past in almost all countries of the world, and a further increase is expected for the future. Besides the well-established effects on type 2 diabetes and cardiovascular disease, there is convincing evidence today that obesity also increases the risk of several types of cancer, including colorectal cancer, postmenopausal breast cancer, endometrial cancer, renal cell carcinoma, esophageal adenocarcinoma, pancreatic cancer, and liver cancer. Obesity probably also increases the risk of ovarian cancer, advanced prostate cancer, gallbladder cancer, and gastric cardia cancer...
2016: Recent Results in Cancer Research
https://www.readbyqxmd.com/read/27909718/enzalutamide-inhibits-proliferation-of-gemcitabine-resistant-bladder-cancer-cells-with-increased-androgen-receptor-expression
#13
Koji Kameyama, Kengo Horie, Kosuke Mizutani, Taku Kato, Yasunori Fujita, Kyojiro Kawakami, Toshio Kojima, Tatsuhiko Miyazaki, Takashi Deguchi, Masafumi Ito
Advanced bladder cancer is treated mainly with gemcitabine and cisplatin, but most patients eventually become resistance. Androgen receptor (AR) signaling has been implicated in bladder cancer as well as other types of cancer including prostate cancer. In this study, we investigated the expression and role of AR in gemcitabine-resistant bladder cancer cells and also the potential of enzalutamide, an AR inhibitor, as a therapeutic for the chemoresistance. First of all, we established gemcitabine-resistant T24 cells (T24GR) from T24 bladder cancer cells and performed gene expression profiling...
November 24, 2016: International Journal of Oncology
https://www.readbyqxmd.com/read/27909626/metastasis-of-prostate-adenocarcinoma-to-the-frontal-and-ethmoid-sinus
#14
Fatih Akdemir, Mustafa Aldemir, Hasan Çakar, Gülnur Güler
Intracranial metastasis of prostate cancer is rarely seen, and there are few studies in this regard in the literature. Most of these studies in the literature comprise the metastasis of prostate cancer to the sphenoid sinus, and metastasis to the frontal and ethmoid sinus is a much rare entity. Association of visual symptoms, epistaxis, headache, and hematuria may indicate a urologic malignancy in terms of the origin of the primary tumor. This study was aimed to present the prostate cancer case of a 73-year-old patient whose paranasal sinus tomograms revealed the presence of frontal and ethmoid sinus metastasis...
December 2016: Turkish Journal of Urology
https://www.readbyqxmd.com/read/27909617/diagnostic-value-of-micrornas-in-prostate-cancer-patients-with-prostate-specific-antigen-psa-levels-between-2-and-10-ng-ml
#15
Serin Akbayır, Necati Muşlu, Sema Erden, Murat Bozlu
OBJECTIVE: Prostate specific antigen (PSA), used for the early diagnosis of prostate cancer (PCa), is one of the best tumour markers known so far. However, in situations when PSA is between 2-10 ng/mL, which is named as grey zone, PSA falls short of distinguishing benign prostate diseases from PCa. On the other hand, it was demonstrated in many previous studies that microRNA (miRNA) could be a marker for cancer. Therefore, in this study, it was aimed to enhance the diagnostic power of PSA, especially with grey zone patients, by the use of miRNA...
December 2016: Turkish Journal of Urology
https://www.readbyqxmd.com/read/27909616/is-extended-pelvic-lymph-node-dissection-for-prostate-cancer-the-only-recommended-option-a-systematic-over-view-of-the-literature
#16
REVIEW
Thomas Rees, Nicholas Raison, Mohammed Iqbal Sheikh, Zahra Jaffry, Sanjeev Madaan, Ben Challacombe, Kamran Ahmed, Prokar Dasgupta
OBJECTIVE: Pelvic lymph node dissection (PLND) is performed alongside radical prostatectomy as the most accurate method of staging prostate cancer. Yet the potential therapeutic benefits of lymphadenectomy are yet to be confirmed. MATERIAL AND METHODS: A PubMed database search was performed to identify all papers comparing techniques for PLND or none. The primary outcome measure was long term oncological outcomes. Studies looking at men with clinically localized prostate cancer at the time of radical prostatectomy who received no adjuvant treatment were included...
December 2016: Turkish Journal of Urology
https://www.readbyqxmd.com/read/27908968/psa-stratified-performance-of-18f-and-68ga-labeled-tracers-in-psma-pet-imaging-of-patients-with-biochemical-recurrence-of-prostate-cancer
#17
Felix Dietlein, Carsten Kobe, Stephan Neubauer, Matthias Schmidt, Simone Stockter, Thomas Fischer, Klaus Schomäcker, Axel Heidenreich, Boris D Zlatopolskiy, Bernd Neumaier, Alexander Drzezga, Markus Dietlein
PURPOSE: Several studies outlined the sensitivity of (68)Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localization of relapsed prostate cancer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemical recurrence. Labeling of PSMA tracers with (18)F offers numerous advantages, including improved image resolution, longer half-life and increased production yields. The aim of this study was to assess the PSA-stratified performance of the (18)F-labeled PSMA tracer (18)F-DCFPyL and the (68)Ga-labeled reference (68)Ga-PSMA-HBED-CC...
December 1, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27908678/avoidance-of-late-rectal-toxicity-after-high-dose-rate-brachytherapy-boost-treatment-for-prostate-cancer
#18
Borut Kragelj, Jernej Zlatic, Lijana Zaletel-Kragelj
PURPOSE: To elucidate potential risk factors important for the appearance of late rectal toxicity (LRT) after high-dose-rate boost treatment (HDRBT) of prostate cancer and to validate the predictive value of the minimal dose to the most exposed 2 cc of rectum received with HDRBT (D2ccrect). METHODS AND MATERIALS: The study of LRT, defined as relative deterioration of defecation problems (RDDP) (stool frequency, pain, rectal bleeding, fecal urgency, and incontinence) during follow-up period, was carried out on 88 patients, consecutively treated from October 2006 through April 2011 with HDRBT of 3 × 6-7 Gy to 50-50...
November 28, 2016: Brachytherapy
https://www.readbyqxmd.com/read/27908592/activation-of-gpr30-stimulates-gtp-binding-of-g%C3%AE-i1-protein-to-sustain-activation-of-erk1-2-in-inhibition-of-prostate-cancer-cell-growth-and-modulates-metastatic-properties
#19
Lau Kin-Mang, Ma Fanny Man-Ting, Xia Jenny Tian, Chan Queeny Kwan Yi, Ng Chi-Fai, To Ka-Fai
Previously, we reported that GPR30 activation by the receptor-specific, non-estrogenic ligand G-1 inhibited in vitro and in vivo growth of prostate cancer (PCa) cells via sustained Erk1/2 activation. Mechanism underlying the sustained Erk1/2 activation for PCa cell growth inhibition remains unclear. Here we report that G-1, through GPR30, activated Gαi1 proteins to sustain Erk1/2 activation but failed to activate adenylyl cyclase (AC) for cAMP production in PCa cells. The chemical-induced activation of AC-cAMP-PKA signaling attenuated Erk1/2 activity and blocked the cell growth inhibitory effects of G-1...
November 28, 2016: Experimental Cell Research
https://www.readbyqxmd.com/read/27908453/volumetric-modulated-arc-therapy-with-dynamic-collimator-rotation-for-improved-multileaf-collimator-tracking-of-the-prostate
#20
Ghulam Murtaza, Jakob Toftegaard, Ehsan Ullah Khan, Per Rugaard Poulsen
PURPOSE: To improve MLC tracking of prostate VMAT plans by dynamic rotation of the collimator to align the MLC leaves with the dominant prostate motion direction. METHODS: For 22 prostate cancer patients, two dual arc VMAT plans were made with (1) fixed collimators (45° and 315°) and (2) a rotating collimator that aligned the MLC leaves with the dominant prostate motion direction (population-based first principal component). The fixed and rotating collimator plan quality was compared using selected dose-volume indices...
November 28, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
keyword
keyword
82207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"